Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

Alexion convinces NICE of Soliris’ value

But recommendation of the expensive 'ultra orphan' drug' comes with conditions

- PMLiVE

Rapid review for Pfizer’s superbug vaccine

FDA to expedite assessment of Clostridium difficile inoculation

- PMLiVE

England’s Cancer Drugs Fund receives new funding boost

Gains an extra £160m to pay for drugs not recommended by NICE

- PMLiVE

NICE wants more data on Boehringer’s Jardiance

Pharma company needs to demonstrate cost-effectiveness of its diabetes drug

Biogen Idec building

Final NICE backing for Biogen Idec’s Tecfidera

Oral multiple sclerosis is cleared for NHS use in England

- PMLiVE

Pfizer and Merck expand anti-PD1 cancer alliance

Will investigate combination of pembrolizumab and Xalkori

- PMLiVE

ViiV bags US approval for HIV blockbuster-in-waiting

Drug combines antiretrovirals with Tivicay

- PMLiVE

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

- PMLiVE

NICE backs Celgene’s Revlimid in bone marrow disorder

Recommends that drug can be used on NHS to treat myelodysplastic syndromes

- PMLiVE

NICE backs Gilead’s Sovaldi in hepatitis C

But health watchdog denies earlier use of Janssen’s Zytiga

- PMLiVE

US panel backs pneumococcal vaccines for seniors

Vaccines to be provided by Merck & Co and Pfizer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links